Drug Profile
SGN CD19B
Alternative Names: SGN-CD19BLatest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals; Seattle Genetics
- Developer Seagen
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma